Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026)

Regeneron Pharmaceuticals' Long-Term Investments history runs 18 years deep, the most recent figure standing at $9.8 billion for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 5.49% year-over-year to $9.8 billion in Q1 2026; TTM through Mar 2026 was $9.8 billion, a 5.49% increase from a year earlier, with the FY2025 full-year figure at $10.3 billion, up 15.29% from the prior year.
• Long-Term Investments slipped to $9.8 billion in Q1 2026 per REGN's latest filing, from $10.3 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $10.3 billion in Q3 2025 and bottomed at $5.4 billion in Q4 2023.
• The 5-year median for Long-Term Investments is $7.1 billion (2022), against an average of $7.7 billion.
• Across the five-year window, Long-Term Investments soared 99.9% in 2022 and slipped 18.13% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $6.6 billion in 2022, then retreated by 18.13% to $5.4 billion in 2023, then soared by 64.92% to $8.9 billion in 2024, then gained by 15.29% to $10.3 billion in 2025, then retreated by 4.63% to $9.8 billion in 2026.
• Per Business Quant, the three latest REGN Long-Term Investments figures stand at $9.8 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.3 billion (Q3 2025).